{"id":"W3048967410","doi":"10.1200/jco.20.01924","title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; Oncology; Internal medicine; BRCA mutation; Ovarian cancer; Bevacizumab; Guideline; PARP inhibitor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase; Polymerase; Biology; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004389175,0.0002912022,0.005844077,0.0001613109,0.00001938378,0.000007495272,0.0004084879,0.0005429314,0.000180231],"category_scores_gemma":[0.0003773997,0.0001483342,0.001834704,0.0004176784,0.0001305021,0.00003371156,0.00009421943,0.001501716,0.0000144269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004507607,"about_ca_system_score_gemma":0.003254066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007597115,"about_ca_topic_score_gemma":0.00003515598,"domain_scores_codex":[0.9914028,0.0007992313,0.006745697,0.0002845911,0.0005492215,0.0002184381],"domain_scores_gemma":[0.9927269,0.001554253,0.004913219,0.0003496286,0.0002111857,0.0002447929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002548387,0.001604311,0.0004444787,0.00313134,0.00268306,0.003838339,0.00003124482,0.000001842013,6.1165e-9,0.0003155531,0.02675224,0.9609427],"study_design_scores_gemma":[0.00433379,0.004237875,0.001469485,0.0148031,0.008457959,0.0002377769,0.00005989689,0.000001703667,1.331155e-7,0.00006632933,0.9662323,0.00009964161],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001843206,0.967513,0.00001167066,0.02577754,0.001799347,0.0008371335,0.00002059675,0.000003215218,0.00401911],"genre_scores_gemma":[0.0001631139,0.9921027,0.00282474,0.001855508,0.002896572,0.00005749221,0.00001017468,0.00002845042,0.00006119369],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9608431,"threshold_uncertainty_score":0.6524292,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2527720037666658,"score_gpt":0.5568653200599185,"score_spread":0.3040933162932528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}